Rival GLP-1 Weight-Loss Drug Emerges From China – U.S. News & World Report
Rival GLP-1 Weight-Loss Drug Emerges From China U.S. News & World Report
Hims & Hers: Devastating GLP-1 News Could Shatter Growth Narrative
Post Content
Rival GLP-1 Weight-Loss Drug Emerges From China
By Dennis Thompson HealthDay ReporterTUESDAY, June 24, 2025 (HealthDay News) — A new Chinese-developed GLP-1 weight loss drug could prove a new…
Dual-Target Weight Loss Treatment Shows Promise
Amycretin — a novel obesity treatment that targets both GLP-1 and amylin receptors — has shown early success in phase 1 testing and will be advanced into phase 3 testing. Medscape Medical News
Rival GLP-1 Weight-Loss Drug Emerges From China – Wyoming News Now
Rival GLP-1 Weight-Loss Drug Emerges From China Wyoming News Now
Is SCHD’s Recent Drawdown a Buying Opportunity Like PEP – Here’s What I Discovered
The recent correction in the Schwab U.S. Dividend Equity ETF (NYSEARCA:SCHD) has many passive income investors wondering if it’s time to load up or jump out. With the S&P 500 on its way to new highs, the dividend stock-heavy SCHD has been in a bit of a tough spot, still down 10% from its own […]
Studies Address Muscle Loss Caused By GLP-1 Drugs
By Dennis Thompson HealthDay ReporterTUESDAY, June 24, 2025 (HealthDay News) — GLP-1 drugs like Ozempic and Zepbound are great at promoting weight…
Hims & Hers: Devastating GLP-1 News Could Shatter Growth Narrative
Post Content
Big Pharma Faceoff: Wegovy To Join Mounjaro In India’s Booming Weight Loss Drug Market
While both drugs belong to the GLP-1 receptor agonist class, Mounjaro has a dual mechanism (GIP and GLP-1), which clinical trials suggest may provide superior weight loss outcomes
Amycretin delivers unprecedented weight loss in early trial for obesity treatment
Once-weekly amycretin, a novel peptide activating GLP-1, amylin, and calcitonin receptors, produced rapid, substantial, and sustained weight loss in adults with overweight or obesity during a phase 1b/2a trial. The treatment was generally well tolerated, with mostly mild to moderate gastrointestinal side effects, supporting further investigation in larger, longer studies.